Celecoxib administration interferes with the anti‐platelet effect of low dose aspirin in canines

• DOI: 10.1096/fasebj.24.1_supplement.574.3
• Publication Date: 2021-06-15T18:36:43Z
• Authors: D Adam Lauver; Ryan A Frieler; William L Smith; Benedict R Lucchesi
• Keywords: Celecoxib; Ex vivo

The purpose of this study was to determine whether simultaneous treatment with celecoxib (CEL) interferes the anti‐platelet effects aspirin (ASA). Patients at risk for adverse cardiovascular events often are prescribed a low dose (81 mg) ASA selectively inhibit cyclooxygenase (COX)‐1 dependent synthesis thromboxane A2 in platelets. Many these patients simultaneously administered COX‐2 specific inhibitor, CEL, pain management. Recent vitro reports demonstrated ability CEL bind COX‐1 thereby slowing rate acetylation critical Ser530 by without otherwise affecting enzyme metabolize arachidonic acid (AA). Therefore, it is important understand might adversely affect beneficial vivo . To test question, dogs were (1.16 or 4.64 mg/kg), (1.43 mg/kg, bid) combination both and period least three days. At conclusion each regimen, blood collected ex platelet aggregation responses recorded. As expected, AA‐induced inhibited doses ASA. administration alone had no effect on aggregation. Simultaneous dose, but not high interfered inhibitory results highlight complex function enzymes hemostatic process.